ASON-DNAzyme Complex Figure 8. ASON-Bulge-DNAzyme can efficiently silence the expression of endogenous cellular genes. BHK21 cells were transfected with 0.25 mg of DNAzyme against integrin b1 in each well of a 24-well plate. RT-PCR was performed at 36 h after transfection. ASON-DNAzyme significantly reduced the mRNA level of integrin b1, but not integrin b3. doi:10.1371/journal.pone.0018629.g008 antibody (Abmart, China). The blot was developed using ECL Plus (Amersham Biosciences). Reporter gene assay BHK-21 cells were harvested and lysed with 200 ml of lysis buffer (0.1 M Tris, 0.1% Triton X-100, 2 mM EDTA, pH 7.8). The eGFP fluorescence was analyzed using a luminometer (Modulus, Turner Biosystems, USA). References 1. Bronson SK, Smithies O (1994) Altering mice by homologous recombination using embryonic stem cells. J Biol Chem 269: 27155–27158. 2. Paterson BM, Roberts BE, Kuff EL (1977) Structural gene identification and making by DNA:mRNA hybrid-arrested cell-free translation. Proc Natl Acad Sci USA 74: 4370–4374. 3. Mizuno T, Chou MY, Inouye M (1984) A unique mechanism regulating gene expression: translational inhibition by a complementary RNA transcript (micRNA). Proc Natl Acad Sci USA 81: 1966–1970. 4. Izant JG, Weintraub H (1984) Inhibition of thymidine kinase gene expression by anti-sense RNA: a molecular approach to genetic analysis. Cell 36: 1007–1015. 5. Pieken WA, Olsen DB, Benseler F, Aurup H, Eckstein F (1991) Kinetic characterization of ribonuclease-resistant 29-modified hammerhead ribozymes. Science 253: 314–317. 6. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, et al. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806–811. 7. Kennerdell JR, Carthew RW (1998) Use of dsRNA-mediated genetic interference to demonstrate that frizzled and frizzled 2 act in the wingless pathway. Cell 95: 1017–1026. 8. Zamecnik PC, Stephenson ML (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Nat Acad Sci USA 75: 280–288. 9. Agrawal S, Zhao Q (1998) Antisense therapeutics. Curr Opin Chem Biol 2: 519–528. 10. Galderisi U, Cascino A, Giordano A (1990) Antisense oligonucleotides as therapeutic agents. J Cell Physiol 181: 251–257. 11. Gewirtz AM (1998) Antisense oligonucleotide therapeutics for human leukemia. Curr Opin Hematol 5: 59–71. 12. Guvakova MA, Yakubov LA, Vlodavsky I, Tonkinson JL, Stein CA (1995) Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem 270: 2620– 2627. Author Contributions Conceived and designed the experiments: JY CL. Performed the experiments: JY CL. Analyzed the data: JY. Contributed reagents/ materials/analysis tools: CL. Wrote the paper: JL. 13. Gao WY, Han FS, Storm C (1992) Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol Pharmacol 41: 223–229. 14. Egholm M, Buchardt O, Christensen L, Behrens C, Freier SM, et al. (1993) PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature 365: 566–568. 15. Breaker RR, Joyce GF (1994) A DNA enzyme that cleaves RNA. Chem Biol 1: 223–229. 16. Santoro SW, Joyce GF (1997) A general purpose RNA cleaving DNAzyme. Proc Natl Acad Sci USA 94: 4262–4266. 17. Breaker RR (2000) Making catalytic DNAs. Science 290: 2095–2096. 18. Sun L-Q, Cairns MJ, Saravolac EG (2000) Catalytic nucleic acids: from lab to applications. Pharmacol Rev 52: 325–347. 19. Silverman SK (2010) DNA as a versatile chemical component for catalysis, encoding, and stereocontrol. Angew Chem Int Ed Engl 49: 7180–7201. 20. Santoro SW, Joyce GF (1998) Mechanism and utility of an RNA-cleaving DNA enzyme. Biochemistry 37: 13330–13342. 21. Kurreck J, Birgit B, Jahnel R, Erdmann VA (2002) Comparative study of DNA enzyme and ribozymes against the same full-length messenger RNA of the vanilloid receptor subtype I. J Biol Chem 277: 7099–7107. 22. Cairns MJ, Hopkins TM, Witherington C, Wang L, Sun L-Q (1999) Target site selection for an RNA-cleaving catalytic DNA. Nat Biotechnol 17: 480–486. 23. Emilsson GM, Breaker RR (2002) Deoxyribozymes New activities and new applications. Cellular and Molecular Life Sciences 59: 596–607. 24. Nielsen PE, Egholm M, Berg RH, Burchardt O (1993) Peptide nucleic acids (PNAs): potential antisense and anti-gene agents. Anticancer Drug Res 8: 53–63. 25. Ota N, Warashina M, Hirano K, Hatanaka K, Taira K (1998) Effects of helical structures formed by the binding arms of DNAzymes and their substrates on catalytic activity. Nucleic Acids Res 26: 3385–3391. 26. Castanotto D, Rossi JJ (2009) The promises and pitfalls of RNA-interference- based therapeutics. Nature 457: 426–4. 27. Lares MR, Rossi JJ, Ouellet DL (2010) RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol 28: 570–579. PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e18629